United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

Key Points

• United Therapeutics CFO James Edgemond sold 10,000 shares on April 30 at an average price of $572.61 for $5.726M, part of multiple late‑March/April sales that cut his direct stake to 18,876 shares—a 34.63% decrease in ownership.
• Shares traded near $570.40 (down 0.2%) with a market cap of about $25.0B and a P/E of 20.44; the stock's 52‑week range is $272.12–$607.89.
• United Therapeutics beat EPS estimates last quarter ($7.70 vs. $6.78) though revenue slightly missed, and analysts remain largely positive (ten Buy, three Hold) with an average price target of $601.50.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,808,586.36. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total transaction of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total transaction of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total transaction of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total transaction of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00.

United Therapeutics Trading Down 0.2%

Shares of NASDAQ:UTHR traded down $0.95 during midday trading on Friday, reaching $570.40. The company had a trading volume of 185,519 shares, compared to its average volume of 478,864. The company's 50 day moving average price is $543.83 and its 200 day moving average price is $497.42. The stock has a market cap of $25.00 billion, a P/E ratio of 20.44, a P/E/G ratio of 1.62 and a beta of 0.75. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm's quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the firm earned $6.19 EPS. Research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on UTHR. UBS Group upped their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Bank of America upped their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. TD Cowen upped their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a report on Monday, March 30th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $601.50.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $48,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.